Startup77’s Post

Cellivate Technologies, a rising star in the biotech industry, has successfully raised $1 million in a seed funding round led by Antler, with support from Venture Catalysts++ | India's 1st Multi-Stage VC, Hatcher+, and We Founder Circle. This fresh infusion of capital will propel the company's research and development (R&D), scale up production, and broaden its market presence, according to Cellivate's latest press release. Founded by Viknish Krishnan-Kutty, PhD, Cellivate Technologies is pioneering advancements in cell culture and biomanufacturing. The company is tackling critical industry challenges with groundbreaking solutions, including its flagship microcarriers that enhance cell growth and a novel serum poised to replace fetal bovine serum (FBS) in cell culture. As the cell culture market, particularly in microcarriers and serum, is anticipated to soar to $33 billion by 2030, Cellivate is strategically positioning itself to become a leading force in this burgeoning sector. Cellivate’s innovations are designed not only to optimize efficiency and reduce costs but also to address ethical concerns tied to traditional cell culture methods. By offering alternatives to animal-derived products, the company’s developments could significantly diminish reliance on animal slaughter. With this new funding, Cellivate is set to advance its R&D, scale production, and expand its market reach, aligning with the increasing demand for sustainable and ethical solutions in biotechnology. #CellivateTechnologies #BioTech #SeedFunding #FundingAlert #FundraiserAlert #Antler #VentureCatalysts #Hatcher+ #WeFoundCircle #VentureCapital #CellCulture #Innovation #SustainableTech #EthicalBiotech #Microcarriers #Biomanufacturing #RAndD #AllBoutCorps

Tierra Biosciences raises $11.4M series A to expand designer protein-to-order platform 👏 "Traditional protein engineering using living cells is slow, inefficient, and data poor. Tierra’s cell-free protein production platform will change the game, powering our customers’ discovery efforts with rapid access to large numbers of discrete custom proteins for screening and discovery, plus fast yield scale-up for downstream development and pilot work." Insightful words from Tierra CEO Mike Nemzek. Corinna X. Chen, Partner at Material Impact, adds, "Tierra’s platform propels innovation in the bioeconomy by eliminating bottlenecks in protein discovery and manufacturing." Now, Tierra has closed an $11.4m Series A round led by Material Impact. The round, which adds to the firm’s $6 million in seed funding and over $7 million in grant funding, was supported by new and existing investors including Prosus Ventures, In-Q-Tel, Hillspire, Freeflow Ventures, Creative Ventures, and Social Capital 💰 Congratulations to Michael Nemzek, Rachel Llanas, Grace Tharmarajah, William Mudge, Matt Zelinski, Brendan Foster, Lexi Kindrick, and the rest of the team at Tierra! Check out the link to the full article in the comments ⬇️ #funding #venturecapital #biotechdiaries Hi, I'm Jeff Bissen (pronounced BEE-sen) 👋 I'm a life science professional with 10 years of experience - first in research, now on the business side of the industry. I also post almost every day about my perspectives on biotech. Interested? Follow my profile and subscribe to my weekly newsletter, Biotech Diaries: https://lnkd.in/e8r_WBP8 ***Views expressed in this post are entirely my own and not necessarily held by any past, present, or future employer***

#fundingalert 💼Company: Ironic Biotech 💰Funding: €1 Million ⚡Round: Pre-Seed 👥Investors: Nordic Foodtech VC. Ironic Biotech, sweden startup was founded in 2020 by Nélida Leiva Eriksson, who holds a PhD in protein design and molecular biology and has worked as a visiting fellow at Harvard and the University of Essex. This Pre-Seed funding will be used for further ramp work, expanding the company’s patent portfolio, and optimizing the production process. The team is now looking for partners in the food and food supplement industry to work with. Nélida Leiva Eriksson Louise Rørbæk Heiberg Karin Kettisen, Ph.D. Read more -https://lnkd.in/erUC9MhT To share your startup story write us on - contact@startuprise.co.uk #IronicBiotech #swedenstartup #biotech #biotechstartup #supplement #molecularbiology #funding #startupnews #fundingnews #news #startuprise

The proposal of SPRIND (German Agency for Disruptive Innovations) to license IP for virtual shares as a standard procedure for start-ups has not met with universal approval. How applicable is such a model to biotechnology start-ups, and can a one-size-fits-all approach really do away with defining market value and negotiating fair and reasonable IP terms? After a keynote, representatives of SPRIND, universities and technology transfer experts will share their experience and discuss their various approaches to start-up creation.   We look forward to the contributions to the panel from Birgit Kerber from and Thomas Hanke and the presentations by: Regina Hodits from Wellington Partners Nicolas Krink from SPRIND - Bundesagentur für Sprunginnovationen Dr. Andrea Schmoll from Osborne Clarke Rainer Wessel from DKFZ Deutsches Krebsforschungszentrum   #IP #Startups #Biotechnology #SPRIND #Technology #Biotech #DBT2024

Loren⚡+ startups 💡= accelerated financial management guidance and back-office experts ready to help you power your vision 📈

As MassBio releases its 5-year strategic plan today, I'm thrilled to share key insights from my recent podcast conversation with Jason Cordeiro, Chief Operating and Innovation Officer. I had no idea about some of these programs, so I bet you'll learn something new even if you think you know all about MassBio! Here are some key takeaways from our conversation: 🌱 Nurturing Early-Stage Companies: MassBio is launching a Launchpad program to provide roadmaps and potential partners for startups, along with plans for a seed fund linked to their MassBio Drive accelerator. 🤖 Embracing AI and Tech: There's a strong focus on supporting AI-driven drug development and "tech for biotech" companies, recognizing the importance of digital innovation in the industry's future. 💰 Expanding Investor Base: MassBio is developing a program to demystify life sciences investing and attract new funders to the sector. 🧬 Fostering Diverse Talent: The successful Biodiversity initiative is expanding, with plans to develop targeted programs in different communities plus a new focus on executive-level talent development in partnership with The Termeer Foundation. 📣 Amplifying Industry Impact: MassBio aims to better communicate the biotech industry's story to lawmakers and the public, emphasizing its broader impact beyond financial metrics. These initiatives are part of MassBio's comprehensive strategy to maintain Massachusetts' leadership in the biotech sector. I'm excited to see how these plans unfold over the next five years! #Biotech #MassBio #Innovation #LifeSciences #AIinHealthcare Don't miss the full conversation! Link to podcast in comments.

As a founding member of Zodel Hub, you can enjoy numerous benefits. Allow me to highlight two of them for you. To start, as a founding member, you can have up to five team members enjoy our workspaces. Furthermore, you will have access to our Investor's Dashboard, providing you with insights into the ongoing activities at Zodel Hub. Now that you are aware of the benefits Zodel Hub offers to the biotech sector, why not join us and become a founding member? Visit our website to join as a founding member of Zodel Hub. If you have any questions, please feel free to contact us at hello@zodelhub.com. #ZodelHubFAQ #ZodelHub #biotechnology #biotechstartup #innovation

𝗦𝘆𝗻𝗕𝗶𝗼 𝗳𝗿𝗼𝗺 𝗟𝗮𝗯 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗩𝗖 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗗𝗲𝗲𝗽 𝗧𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀 Synthetic biology (#SynBio) isn't just about science; it's also about how these scientific innovations are turned into products and solutions that meet market needs. Its applications are extensive, ranging from enhancing food flavors to revolutionizing carbon sequestration practices through innovative uses of natural systems and genetic engineering. However, the path from #lab to #market can be challenging for #founders, from building a scalable plan to navigating regulatory matters. We had the pleasure of hosting Chloë Payne, Principal at Ponderosa Ventures, to cover the basics of the SynBio industry and help aspiring #STEM founders take their first steps into #entrepreneurship. Key themes covered: 🧬 Understanding Synthetic Biology (SynBio) and Its Applications 🗺️ Navigating Regulatory Scenarios in the Food Industry 🎯 Pricing Strategy Basics for SynBio Innovations 📈 Capital Efficiency and Scalability in Synthetic Biology Innovation 🎯 Green Lights and Red Flags for VCs in Early-Stage SynBio > Catch the full conversation here: https://lnkd.in/ebQp34tm #startup #startups #innovation #technology #manufacturing #industry #vcs #venturecapital #techtransfer #deeptech #hardtech #industry #tech #strategy #founders #technology #phd #science #foodtech #biotech #DeepTechCatalyst ----- 📣 Follow The Scenarionist to get exclusive insights at the intersection of Deep Tech and Venture Capital, every week!

Biotech and Cleantech sectors are on the rise! 🚀🌿 Despite the market slump in recent years, the signs of recovery keep on coming... - In Q2 2024, the biotech sector saw a significant rebound, with total deal value surpassing that of 2023. - The average capital raised per follow-on round increased by 47% compared to 2023 = growing investor confidence 💰🌟 - The global startup funding in Q2 2024 reached $79 billion, up 12% from Q2 2023, with much of that coming from the biotech sector 📈 Here are some (of many!) exciting funding milestones that deserve a shout-out: 1️⃣ LabGenius raised £35 million in a Series B round, led by M Ventures, to advance their ML-driven drug discovery platform. Congrats to James Field and the team! 🧬 2️⃣ Onego Bio secured €14 million to scale their animal-free egg protein, Bioalbumen®. Kudos to Maija Itkonen and the team for pushing the boundaries of sustainable food tech! 🥚 3️⃣ RebrAIn completed a €3.7 million seed round, led by Karista, enhancing their precision neurosurgery solutions. Big shoutout to David C. and the team! 🧠 4️⃣ AmphiStar raised €6 million to expand production of eco-friendly biosurfactants. Congratulations to Pierre-Franck VALENTIN and the AmphiStar team for their green innovations! 🌿 5️⃣ Insempra completed a $20 million Series A round to develop sustainable, bio-based ingredients for food and cosmetics. Nice work, Jens Klein and the Insempra team for driving innovation in biomanufacturing! 🌿🔬 Seeing success stories like this really is very promising for what's to come... Onwards and upwards!! #Biotech #Funding #Innovation #Sustainability #HealthTech

Very insightful panel discussion moderated by Lynn Pieper Lewis of Gilmartin Group LLC with John Boyce of TigerGene LLC and Reetika B. of ARCH Venture Partners. Some main topics covered in the discussion were the need for startups executive teams s To show flexibility and willingness to pivot, the importance of an exit strategy when pitching for funding, and the difference between a “cool science” and a science with a clearly defined market, there’s a big difference. LSX USA Congress LSX - partnering for Life Science eXecutives #biotech #medtech #healthtech #scienceandtechnology #lifescience #biotechnology #drugdevelopment #marketing #networking #webdesign